Longeveron publishes stem cell therapy frailty trial results
Longeveron published Phase 2b results in Cell Stem Cell showing its allogeneic mesenchymal stem cell therapy improved physical function in older adults with frailty. The study reported gait-speed gains and no new safety concerns, and the company says findings support larger trials.
Why it mattersPhase 2b Cell Stem Cell publication reports gait-speed improvements and tolerability.
Entities Mentioned
LongeveronCell Stem Cell